Cargando…

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells

Increasing evidence shows that c-Myc oncoprotein is tightly associated with multiple myeloma (MM) progression. Herein, we identified compound 7594-0035, which is a novel inhibitor that specifically targets c-Myc. It was identified from the ChemDiv compound database by molecular docking-based, high-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Ruosi, Sun, Xiaoyang, Xie, Yu, Sun, Xiaoshen, Yao, Yao, Li, Hujun, Li, Zhenyu, Gao, Jian, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146296/ https://www.ncbi.nlm.nih.gov/pubmed/30068698 http://dx.doi.org/10.1042/BSR20181027

Ejemplares similares

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
por: Sun, Xiaoyang, et al.
Publicado: (2019)

Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma
por: Yao, Ruosi, et al.
Publicado: (2020)

Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
por: Yao, Ruosi, et al.
Publicado: (2022)

Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells
por: Yao, Yao, et al.
Publicado: (2016)

Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation
por: Liu, Linlin, et al.
Publicado: (2018)

MYC inhibitors in multiple myeloma
por: Martínez-Martín, Sandra, et al.
Publicado: (2021)

Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments
por: Zhou, Jian, et al.
Publicado: (2021)

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
por: Xia, Jieyun, et al.
Publicado: (2023)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2015)

Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma
por: Njomen, Evert, et al.
Publicado: (2022)

Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer
por: Seo, Ho Kyung, et al.
Publicado: (2014)

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2018)

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
por: Xia, Jieyun, et al.
Publicado: (2023)

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
por: Cao, Yang, et al.
Publicado: (2021)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4‐MYC oncogenic axis in multiple myeloma
por: Agnarelli, Alessandro, et al.
Publicado: (2022)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells
por: Yu, Zhenlong, et al.
Publicado: (2016)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma
por: Håland, Erling, et al.
Publicado: (2022)

Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation
por: Effenberger, Madlen, et al.
Publicado: (2017)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
por: Ortiz-Ruiz, Alejandra, et al.
Publicado: (2021)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
por: Hasan Bou Issa, L., et al.
Publicado: (2022)

Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells
por: Wang, Jiandong, et al.
Publicado: (2014)

Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase
por: Dorasamy, Mathura Subangari, et al.
Publicado: (2017)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer
por: Esser, Alison K., et al.
Publicado: (2020)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

A new hope for patients suffering from multiple myeloma
por: Yu, Jinhua, et al.
Publicado: (2013)

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
por: Sharma, Neeraj, et al.
Publicado: (2021)

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
por: Faruq, Omar, et al.
Publicado: (2022)

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population
por: Wang, Yajun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pf6qudbda27spn5cbma87rno8q